GO
| HSI1 | 25,978.07 | +62.87 | 236.72B |
| HSCEI1 | 8,775.62 | +42.99 | 76.71B |
| Back Zoom + Zoom - Block Traded | |
|
2026-04-24 10:18:58 Regarding yesterday's (23rd) hefty sell-off among Chinese biotech and pharmaceutical stocks, JPMorgan said in its report that it seemed to have been sparked by profit-taking decisions as a result of position adjustments rather than any fundamental deterioration. JPMorgan considered this pullback as a good entry opportunity to build positions in China's healthcare sector ahead of the next wave of catalyst-driven upside. The broker preferred the biotech and CXO (clinical trial service providers) sub-sectors, with INNOVENT BIO (01801.HK), SKB BIO (06990.HK), WUXI APPTEC (02359.HK), and WUXI XDC (02268.HK) as its top picks. ~ AAStocks Financial News Web Site: www.aastocks.com | |